Putnam Fl Investment Management Co adds Regeneron Pharmaceuticals Inc (REGN) to its portfolio

Regeneron Pharmaceuticals Inc (REGN) : Putnam Fl Investment Management Co added new position in Regeneron Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 14,862 shares of Regeneron Pharmaceuticals Inc which is valued at $6,559,641 , the company said in a statement filed on Aug 1, 2016 with the SEC.Regeneron Pharmaceuticals Inc makes up approximately 0.75% of Putnam Fl Investment Management Co’s portfolio.

Other Hedge Funds, Including , Shelton Capital Management boosted its stake in REGN in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 6,789 shares of Regeneron Pharmaceuticals Inc which is valued at $2,996,461. Regeneron Pharmaceuticals Inc makes up approx 0.26% of Shelton Capital Management’s portfolio. Herndon Capital Management added REGN to its portfolio by purchasing 7 company shares during the most recent quarter which is valued at $2,976.Banced Corp reduced its stake in REGN by selling 490 shares or 29.84% in the most recent quarter. The Hedge Fund company now holds 1,152 shares of REGN which is valued at $419,904. Regeneron Pharmaceuticals Inc makes up approx 0.73% of Banced Corp’s portfolio.

Regeneron Pharmaceuticals Inc closed down -7.97 points or -1.81% at $433.4 with 20,26,865 shares getting traded on Thursday. Post opening the session at $443.29, the shares hit an intraday low of $417.5 and an intraday high of $443.99 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.

Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.

Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Regeneron Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Regeneron Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.